By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) on Thursday reported positive topline phase 2 data for pozelimab in patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH.
The Tarrytown, N.Y., biotechnology company, said results from initial six-patient cohort show pozelimab reduced the abnormal destruction of red blood cells, known as hemolysis, with patients achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase.
Regeneron said it has initiated the second part of the phase 2 trial, adding that plans for a phase 3 program are underway.
Write to Colin Kellaher at firstname.lastname@example.org